Skip to main content
. 2022 Sep 29;13:842468. doi: 10.3389/fimmu.2022.842468

Figure 2.

Figure 2

S1-, RBD-, S2-, and NP-specific IgG and IgA in SARS CoV-2+ vs SARS-CoV-2− BAL. (A) S1-, S2-, RBD-, and NP-specific IgG and IgA responses in SARS-CoV-2+ BAL (B) S1-, S2-, RBD-, and NP-specific IgG and IgA responses in SARS-CoV-2− BAL. (A, B) Proportion of specific IgG or IgA over total IgG or IgA measured by ELISA. Specific (OD450)/total IgA or G (μg/ml) are shown. p-Values were calculated by using Mann–Whitney test: *, p < 0.05; **, p < 0.01; ***, p < 0.005. (C) Correlations between specific S1-, RBD-, S2-, and NP-specific IgG antibodies in SARS-CoV-2+ BAL (red dots) and SARS-CoV-2− BAL (gray dots) and onset of symptom to sampling date (days). (D) Correlations between S1-, RBD-, S2-, and NP-specific IgA antibodies SARS-CoV-2+ BAL (red dots) and SARS-CoV-2− BAL (gray dots) and onset of symptom to sampling date (days). (E) Correlation between specific S1, RBD, S2, and NP IgA and IgG antibodies in SARS-CoV-2+ BAL individuals. (F) Correlation between S1-, RBD-, S2-, and NP-specific IgA and IgG in SARS-CoV-2− BAL individuals. All correlations were calculated using Spearman’s test. RBD, receptor-binding domain; NP, nucleocapsid protein.